Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus TORECAN.
PROMETHAZINE DM vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic